(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Lego's $650 Pokémon set is already sold out as demand, preorders surge- 'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream'
- Favored Vehicle for Seniors: Make Your Determination
- I'm a hypnotherapist who helps day traders who are losing money. Here's why I think hypnosis works.
- Overlooked infertility care should be part of national health services, says WHO
- A Gustav Klimt painting is now the most expensive piece of modern art sold at auction. The fascinating history behind the $236 million 'Portrait of Elisabeth Lederer.'
- Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
- 4 Energy-Proficient Clothes washers to Consider in 2024
- US FDA declines to approve Corcept's drug for rare hormonal disorder
